Literature DB >> 18545916

A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate.

Alessio De Ciantis1, Marco Muti, Carlo Piccolini, Massimo Principi, Antonio Di Renzo, Rita De Ciantis, Domenico Frondizi, Gregorio Iannone, Pierfausto Ottaviano, Massimo Piccirilli.   

Abstract

Topiramate (TPM) is a new antiepileptic drug approved for the prevention of migraine headache. However its use is limited by treatment-emergent adverse events; in particular, therapy can exert profound impact on language function. In this investigation, we used functional magnetic resonance imaging (fMRI) to study the anatomofunctional correlates of language disturbances in TPM patients experiencing subjective cognitive impairment. Ten right-handed individuals receiving therapy (five with and five without language disfluency) and five matched healthy control subjects took part in this study. During fMRI subjects alternately rested and performed a word-generating task. The task comprised the silent generation of words beginning with a different input letter visually presented. The activation paradigm consisted of six activation blocks alternating with six baseline rest blocks. The main fMRI measure was the pattern activation of the prefrontal regions (Brodmann's areas 44, 45, and 46) in both left and right hemispheres. Patients receiving TPM (50-100 mg/day) significantly reduced mean monthly migraine frequency. However several differences in fMRI activation were evident in the subject group comparison. Notably, changes in brain activity were observed during the phonemic task in patients with language disturbances. It is likely that TPM therapy is associated with a "remapping" of the language cerebral network.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18545916     DOI: 10.1007/s10072-008-0906-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  4 in total

1.  Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy.

Authors:  Jacobus F A Jansen; Albert P Aldenkamp; H J Marian Majoie; Rianne P Reijs; Marc C T F M de Krom; Paul A M Hofman; M Eline Kooi; Klaas Nicolay; Walter H Backes
Journal:  Epilepsy Behav       Date:  2006-06-21       Impact factor: 2.937

2.  Effects of topiramate on cognitive function.

Authors:  P J Thompson; S A Baxendale; J S Duncan; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

3.  Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.

Authors:  G Bussone; H-C Diener; J Pfeil; S Schwalen
Journal:  Int J Clin Pract       Date:  2005-08       Impact factor: 2.503

4.  Topiramate for migraine prevention: a randomized controlled trial.

Authors:  Jan Lewis Brandes; Joel R Saper; Merle Diamond; James R Couch; Donald W Lewis; Jennifer Schmitt; Walter Neto; Stefan Schwabe; David Jacobs
Journal:  JAMA       Date:  2004-02-25       Impact factor: 56.272

  4 in total
  12 in total

Review 1.  The effects of antiepileptic drugs on cognitive functional magnetic resonance imaging.

Authors:  Guilherme Coco Beltramini; Fernando Cendes; Clarissa Lin Yasuda
Journal:  Quant Imaging Med Surg       Date:  2015-04

2.  The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory.

Authors:  S E Marino; S V S Pakhomov; S Han; K L Anderson; M Ding; L E Eberly; D W Loring; C Hawkins-Taylor; J O Rarick; I E Leppik; J E Cibula; A K Birnbaum
Journal:  Epilepsy Behav       Date:  2012-05-30       Impact factor: 2.937

3.  Severity of Topiramate-Related Working Memory Impairment Is Modulated by Plasma Concentration and Working Memory Capacity.

Authors:  Samuel P Callisto; Sílvia M Illamola; Angela K Birnbaum; Christopher M Barkley; Sai Praneeth R Bathena; Ilo E Leppik; Susan E Marino
Journal:  J Clin Pharmacol       Date:  2020-04-16       Impact factor: 3.126

Review 4.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12

Review 5.  Language Dysfunction in Pediatric Epilepsy.

Authors:  Fiona M Baumer; Aaron L Cardon; Brenda E Porter
Journal:  J Pediatr       Date:  2017-12-11       Impact factor: 4.406

Review 6.  Pharmaco fMRI: Determining the functional anatomy of the effects of medication.

Authors:  Britta Wandschneider; Matthias J Koepp
Journal:  Neuroimage Clin       Date:  2016-10-04       Impact factor: 4.881

7.  Chronic antiepileptic drug use and functional network efficiency: A functional magnetic resonance imaging study.

Authors:  Tamar M van Veenendaal; Dominique M IJff; Albert P Aldenkamp; Richard H C Lazeron; Paul A M Hofman; Anton J A de Louw; Walter H Backes; Jacobus F A Jansen
Journal:  World J Radiol       Date:  2017-06-28

8.  Effect of topiramate and zonisamide on fMRI cognitive networks.

Authors:  Britta Wandschneider; Jane Burdett; Lucy Townsend; Andrea Hill; Pamela J Thompson; John S Duncan; Matthias J Koepp
Journal:  Neurology       Date:  2017-02-17       Impact factor: 9.910

9.  The effect of topiramate on cognitive fMRI.

Authors:  Clarissa Lin Yasuda; Maria Centeno; Christian Vollmar; Jason Stretton; Mark Symms; Fernando Cendes; Mitul A Mehta; Pamela Thompson; John S Duncan; Matthias J Koepp
Journal:  Epilepsy Res       Date:  2013-01-17       Impact factor: 3.045

10.  Effects of carbamazepine and lamotrigine on functional magnetic resonance imaging cognitive networks.

Authors:  Fenglai Xiao; Lorenzo Caciagli; Britta Wandschneider; Josemir W Sander; Meneka Sidhu; Gavin Winston; Jane Burdett; Karin Trimmel; Andrea Hill; Christian Vollmar; Sjoerd B Vos; Sebastien Ourselin; Pamela J Thompson; Dong Zhou; John S Duncan; Matthias J Koepp
Journal:  Epilepsia       Date:  2018-06-13       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.